z-logo
open-access-imgOpen Access
Characterization of a new TEM-derived beta-lactamase produced in a Serratia marcescens strain
Author(s) -
Mariagrazia Perilli,
Antonio Felici,
Nicola Franceschini,
Augusta De Santis,
Laura Pagani,
Francesco Luzzaro,
A Oratore,
Gian María Rossolini,
James R. Knox,
Gianfranco Amicosante
Publication year - 1997
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.41.11.2374
Subject(s) - aztreonam , serratia marcescens , ceftazidime , clavulanic acid , enzyme , microbiology and biotechnology , amp resistance , strain (injury) , point mutation , biology , cefotaxime , tripeptide , enzyme kinetics , chemistry , ampicillin , bacteria , biochemistry , escherichia coli , antibiotics , amino acid , gene , genetics , mutation , active site , amoxicillin , anatomy , pseudomonas aeruginosa
A natural TEM variant beta-lactamase was isolated from an epidemic strain of Serratia marcescens. Nucleotide gene sequencing revealed multiple point mutations located in the 42-to-44 tripeptide and positions 145 to 146, 178, and 238. In addition, a glutamic acid 212 deletion was also found. The purified enzyme was studied from a kinetic point of view, revealing the highest catalytic efficiency (k[cat]/Km) values for ceftazidime and aztreonam compared with the TEM-1 prototype enzyme. The in vitro resistance correlated with kinetic parameters, and the enzyme also mediated resistance to some penicillins and an ampicillin-clavulanic acid combination. The mutational and kinetic changes are discussed in relation to the three-dimensional crystallographic structure of the wild-type TEM-1 enzyme.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom